UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934
Date of Report (date of earliest event reported): September 20, 2006
PEDIATRIX MEDICAL GROUP, INC.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
Florida
|
|
001-12111
|
|
65-0271219 |
|
|
|
|
|
(State or Other
Jurisdiction of
Incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.) |
1301 Concord Terrace
Sunrise, Florida 33323
(Address of principal executive office)
Registrants telephone number, including area code (954) 384-0175
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-com mencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c
Item 1.01. Entry Into a Material Definitive Agreement.
On September 21, 2006, Pediatrix Medical Group, Inc. (the Company or
Pediatrix) announced that it has finalized its previously announced agreement in
principle (the Settlement Agreement) with the U.S. Department of Justice to settle the
governments national Medicaid and TRICARE investigation. Under the terms of the Settlement
Agreement, the Company has paid the federal government $25.1 million related to neonatal services
provided from January 1996 through December 1999. In addition, Pediatrix will enter into separate
state settlement agreements for each state Medicaid program involved in the settlement based on a
model state settlement agreement (the Model State Settlement Agreement). Copies of the
Settlement Agreement and the Model State Settlement Agreement are attached as Exhibits 10.1 and
10.2, respectively, to this Current Report on Form 8-K and are hereby incorporated by reference in
their entirety by reference thereto.
As part of the settlement, Pediatrix has entered into a five-year corporate integrity
agreement with the Office of the Inspector General of the Department of Health and Human Services
(the Corporate Integrity Agreement). The Corporate Integrity Agreement acknowledges the
existence of Pediatrixs comprehensive compliance program and provides for certain other
compliance-related activities during the term of the agreement. A copy of the Corporate Integrity
Agreement is attached as Exhibit 10.3 to this Current Report on Form 8-K and is hereby incorporated
by reference in its entirety by reference thereto.
Item 8.01. Other Events.
On September 21, 2006, Pediatrix issued a press release (the Press Release)
announcing that it has finalized the Settlement Agreement and entered into the Corporate Integrity
Agreement. A copy of the Press Release is attached as Exhibit 99.1 to this Current Report on Form
8-K and is hereby incorporated by reference in its entirety by reference thereto.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
|
|
|
10.1
|
|
Settlement Agreement dated September 21, 2006, between Pediatrix and the
U.S. Department of Justice. |
|
|
|
10.2
|
|
Model State Settlement Agreement. |
|
|
|
10.3
|
|
Corporate Integrity Agreement dated September 20, 2006, between Pediatrix and
the Office of the Inspector General of the Department of Health and Human Services. |
|
|
|
99.1
|
|
Press Release dated September 21, 2006. |
2